Page 4
MARKET & COMPANIES NEWS
Bayer Ukraine has appointed new
Chief and financial director Valenta Farm will liquidate its
Ukraininan subsidary
On Aug 4,
2015, Bayer
has appointed
Jens Behrens
as a new Chief
and financial
director
of Bayer
Company in
Ukraine. Mr.
Behrens has
replaced Christoph Henze at this
position, who by his turn had
taken the position of financial
director of Central America and
the Caribbean division of Bayer
Corporation.
Jens Behrens have been working
in Bayer for more than 30 years;
he has an experience of working
in regions like China, Hong Kong,
Taiwan, Japan, Europe and the
USA. His previous position was
a Head of corporate support
service of Bayer HealthCare
business group in China.
“I am very happy that got an
opportunity to lead the Bayer
Company in Ukraine. It is an honor
and great responsibility to work in
the country that is on the verge
of real changes,” Mr. Behrens
said. “In Bayer, we are confident
that future changes will open
more opportunities for people
and business. I see my prior
task in strengthening long-term
and trustful cooperation with all
customers and partners of Bayer
in Ukraine, and to do this I am
ready to use my global experience
and knowledge gained during my
career”.
Bayer started its activity in
Ukraine in 1992 and currently
Ukrainian company of Bayer has
a stuff amounting more than 500
employees. On Aug 6,
2015, the Board
of directors
of Russian
pharmaceutical
company
“Valenta Farm” decided to
liquidate its subsidiary in Ukraine.
The former Head of Ukrainian
subsidiary, Elena Babich had been
appointed as person responsible
for its liquidation, started on Sept
1, 2015.
LLC “Valenta Farm” is a Russian
pharmaceutical company,
which was founded in 1997.
The company is engaged in
development, production and
market launch of Rx and OTS
drugs of the following therapeutic
areas: psychoneurology, urology,
gastroenterology, immunology,
virology and antibacterial therapy.
Actovegin’s “drug” status was
confirmed
On Sept 14,
2015, “Takeda
Ukraine” received
the confirmation from the MoH
of Ukraine regarding recognition
of “Actovegin” (metabolism
stimulating preparation) as a
drug. Previously in Jun 2015,
the Security Service of Ukraine
had doubts on efficiency of
“Actovegin”, suspecting “Takeda
Ukraine” in collusion with the
State expert center of the MoH
of Ukraine for the purpose of
registration of “Actovegin”, being
in State authority’s opinion a
biologically active additive, as a
drug.
The Japanese subsidiary were
refuting suspicions, stating that
its bestselling drug has been
registered as an Rx drug in
Ukraine for 26 years; likewise,
it was also registered in 21
countries worldwide.
After appealing to the President
of Ukraine, Prime minister of
Ukraine and other authorized
persons, asking to clarify the
situation, “Takeda Ukraine”
achieved the confirmation
on “Actovegin’s” drug status
and validity of its registration
procedures.
Supervisiory Board and Audit
Commission of “Galychfarm” are to
be reelected
On Sept 18, 2015, the
shareholders of Lviv-based
pharmaceutical company
“Galychfarm” made a decision to
re-elect the Supervisory Board
and the Audit Commission of the
company at the extraordinary
meeting, appointed at Oct 27,
2015.
“Galychfarm” is a Ukrainian
leading producer specializing on
production of herbal-chemical
substances based on the
extraction of herbal raw materials.
The company together with
“Kievmedpreparat” is a part of
Arterium Corporation, controlled
by “Finances and Credit” financial
group.
The decision of “Galychfarm’s”
shareholders may be related to
the bankruptcy of “Finances and
Credit” approved by the NBU
on Sept 17, 2015. To date, it is
unclear what will happen to the
non-core assets of Konstantin
Zhevago – the main beneficiary of
“Finances and Credit”. According
the NBU Head, the non-core
assets, which include Zhevago’s
pharmaceutical business, could be
pledged or sold.
U krainian P harmaceutical M arket M onthly : S eptember /A ugust 2015